Insider trade

Dexcom (DXCM)Officer sold ~$229K

Jacob Steven Leach, Officer at Dexcom, sold ~$229K of Dexcom shares.

~$229K
Approx. value · 2,634 sh @ $86.91
269K
Holds after · shares reported
Traded
Jan 29, 2025
Filed
Jan 30, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Dec 16, 2024Insider · 4 peopleInsiders: 4 sales (~$224K)
  2. Dec 31, 2024CongressDisclosed sale of DXCM — reported range $50,001 - $100,000
  3. Jan 27, 2025FDARecall: Dexcom G6, Continuous Glucose Monitoring System, REF: STK-OR-001
  4. Jan 27, 2025FDARecall: Dexcom G6, Continuous Glucose Monitoring System, REFs: STK-OM-001, STR-OM-001, STR-OR-001
  5. Jan 27, 2025FDARecall: Dexcom G6, Continuous Glucose Monitoring System, REF: STK-OE-001
  6. Jan 29, 2025 · this disclosureInsiderOfficer sold ~$229K of DXCM shares in the open market

What came next

  1. Jan 29, 2025Insider · 4 peopleInsiders: 4 sales (~$3.4M)
  2. Feb 25, 2025CongressDisclosed purchase of DXCM — reported range $1,001 - $15,000
  3. Mar 10, 2025Insider · 1 personInsiders: 3 sales (~$517K)
  4. Mar 12, 2025Insider · 5 peopleInsiders: 5 sales (~$5.8M)
  5. Mar 17, 2025InsiderDirector sold ~$25K of DXCM shares in the open market
  6. Apr 7, 2025CongressDisclosed sale of DXCM — reported range $15,001 - $50,000
  7. Apr 8, 2025CongressDisclosed sale of DXCM — reported range $1,001 - $15,000
  8. Apr 9, 2025FDAFDA device clearance: Dexcom G7 15 Day Continuous Glucose Monitoring System
  9. May 5, 2025FDARecall: Dexcom G7 iOS Application, Ref: SW12300 used in conjunction with the Dexcom G7 Continuous Glucose Monitoring (CGM) system
  10. May 12, 2025FDARecall: Dexcom One+ Continuous Glucose Monitoring System, SKU(Part Number): STK-D7-013 (MT28285-1), STK-D7-014 (MT28285-1), STK-D7-103 (MT28285-2)
  11. May 12, 2025FDARecall: Dexcom One Continuous Glucose Monitoring System, SKUs(Part Number): STK-DO-006 (MT27409-1), STK-DO-013 (MT27409-1), STK-DO-103 (MT27409-2), STK-DO-109 (MT27409…
  12. May 12, 2025FDARecall: Dexcom G6 Glucose Receiver, SKUs (Part Number): STK-FM-001 (MT27408-1) & STK-FR-001 (MT27408-1)
  13. May 12, 2025FDARecall: Dexcom G7 Glucose Receiver, SKUs (part number): STK-AT-011(MT26403-0), STK-AT-012 (MT26403-0), STK-AT-013 (MT26403-0), STK-GT-001 (MT26403-1), STK-GT-008 (MT26…
  14. May 23, 2025InsiderOfficer sold ~$843K of DXCM shares in the open market
  15. May 27, 2025InsiderOfficer sold ~$526K of DXCM shares in the open market
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Dexcom

For Dexcom, OQRO holds 20 insider filings (SEC Form 4 or Form 144) and 16 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its DXCM page.

Other recent filings by Jacob Steven Leach, EVP, Chief Operating Officer

The full history of Jacob Steven Leach, EVP, Chief Operating Officer is on the profile page.

How this filing works

Other disclosures at Dexcom

Everything OQRO holds on this company is on its DXCM page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data